Propoxyphene/acetaminophen was a prescription painkiller that combined a mild opioid (propoxyphene, also sold under the brand name Darvon) with acetaminophen to treat mild to moderate pain. It was pulled from the U.S. market in November 2010 after accumulating evidence that propoxyphene could cause dangerous heart rhythm changes, even at recommended doses. If you still have bottles of this medication at home, or you’ve encountered the name on an old prescription record, the short version is that it is no longer legally available in the United States, the European Union, the United Kingdom, or India, and safer alternatives have largely replaced it.
What the Combination Was Designed to Do
Propoxyphene is a synthetic opioid structurally related to methadone, though considerably weaker. By pairing it with acetaminophen, manufacturers aimed to get two different pain-relieving mechanisms working at once: the opioid component acting on pain receptors in the central nervous system, and acetaminophen reducing pain through a separate pathway. The combination was sold under brand names like Darvocet-N (propoxyphene napsylate with acetaminophen) and was one of the most commonly prescribed painkillers in the United States for decades, particularly for conditions like arthritis, dental pain, and post-surgical discomfort.
In practice, propoxyphene was never a strong painkiller. A randomized trial comparing propoxyphene/acetaminophen to tramadol/acetaminophen for post-operative wound pain found that tramadol/acetaminophen provided significantly better pain relief at both one hour and four hours after dosing, while side effects like drowsiness, dizziness, and skin itching were similar between the two drugs.1PubMed Central. Analgesic efficacy of tramadol/acetaminophen and propoxyphene/acetaminophen for relief of postoperative wound pain Critics had argued for years that propoxyphene offered little more pain relief than acetaminophen alone, making the added risks of an opioid component hard to justify.
The Heart Problem That Ended It
The central safety concern with propoxyphene turned out to be its effect on the heart’s electrical system. Propoxyphene blocks sodium channels in heart muscle cells in a way that slows the electrical signals coordinating each heartbeat. Research demonstrated that this blockade was “use-dependent,” meaning it worsened as heart rate increased, and that recovery from the block was remarkably slow, with recovery time constants averaging around 21 seconds. For comparison, lidocaine, a drug that also blocks sodium channels but is considered much safer for the heart, showed recovery time constants of just two to three seconds.2JCI Insight. Marked QRS complex abnormalities and sodium channel blockade by propoxyphene reversed with lidocaine That slow recovery meant propoxyphene could progressively accumulate its blocking effect on the heart with each beat, widening the QRS complex on an electrocardiogram and potentially triggering fatal arrhythmias.
Beyond the sodium channel issue, propoxyphene was also linked to QT interval prolongation, another marker of cardiac risk that can precede a type of irregular heartbeat called torsades de pointes. The FDA ultimately concluded that the cardiac risks outweighed the drug’s modest clinical benefit, and propoxyphene-containing products were voluntarily withdrawn from the U.S. market.3PubMed Central. QTc interval prolongation by d-propoxyphene: what about other analgesics? This was not an overnight decision. Calls to ban propoxyphene as an “imminent hazard to public health” had been made as early as the late 1970s.4JAMA. Propoxyphene: Is It a Hazard to Health?
Why the Drug Built Up to Dangerous Levels
One of propoxyphene’s most treacherous properties was its pharmacokinetics, the way the body absorbed, processed, and eliminated it. After a single dose, propoxyphene had a relatively short half-life of about 3.3 hours, which sounds manageable. But with repeated dosing, the picture changed dramatically. The half-life stretched to nearly 12 hours, and the drug’s clearance from the body dropped by roughly half. Both propoxyphene and its main metabolite, norpropoxyphene, accumulated to levels five to seven times higher than what a single dose would produce.5PubMed. Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene
Norpropoxyphene deserves special attention here. This metabolite is pharmacologically active and itself contributes to cardiac toxicity, but the body eliminates it even more slowly than the parent drug. During repeated dosing, norpropoxyphene’s half-life ballooned from about 6 hours to nearly 40 hours. In patients who had been taking propoxyphene long-term, steady-state levels of norpropoxyphene exceeded those of propoxyphene by a factor of 13.6PubMed. Propoxyphene and norpropoxyphene kinetics after single and repeated doses of propoxyphene This accumulation meant that someone taking the drug exactly as prescribed could gradually reach blood levels far higher than expected, and the cardiac risk compounded silently over days and weeks.
How Your Liver Processes Propoxyphene and Why That Matters
Propoxyphene is broken down primarily by a liver enzyme called CYP3A4, which converts it to norpropoxyphene. Research confirmed that another commonly discussed liver enzyme, CYP2D6, plays essentially no role in this process. People who are poor metabolizers through the CYP2D6 pathway showed no meaningful difference in how they handled propoxyphene compared to normal metabolizers.7Taylor & Francis Online (Xenobiotica). CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement
The practical consequence is that anything affecting CYP3A4 activity can alter propoxyphene levels. Many common medications and even foods like grapefruit juice are known to inhibit CYP3A4, and taking these alongside propoxyphene could have slowed its breakdown, leading to higher and more dangerous blood levels. Conversely, drugs that ramp up CYP3A4 activity could speed metabolism of propoxyphene but potentially increase production of the cardiotoxic metabolite norpropoxyphene. This enzyme dependency also helps explain the wide variability in how different people responded to the same dose: individual differences in CYP3A4 expression meant one person’s safe dose could be another person’s dangerous one.8Taylor & Francis Online (Xenobiotica). CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement
Older Adults Faced the Highest Risks
Propoxyphene was disproportionately prescribed to older adults, who were also the population most vulnerable to its harms. A cohort study of adults aged 65 and older found that propoxyphene use was associated with an increased risk of hip fracture, likely due to the drug’s sedating and dizziness-inducing effects combined with the general frailty of older patients.9PubMed. Propoxyphene use and risk for hip fractures in older adults Hip fractures in the elderly carry their own serious mortality risk, so this was not a minor side note.
The pharmacokinetic problems described earlier hit older adults especially hard. Kidney function declines with age, and since norpropoxyphene is cleared partly through the kidneys, older adults were more likely to accumulate the cardiotoxic metabolite to dangerous levels. Reduced liver function, which is also common in aging, further slowed drug clearance. And because older adults are more likely to take multiple medications, the chances of a CYP3A4-mediated drug interaction were higher. Propoxyphene had appeared on the Beers Criteria, a widely used list of medications considered potentially inappropriate for older adults, well before its eventual withdrawal.
A Global Withdrawal, Not Just an American One
The United States was actually late to the party when it came to removing propoxyphene from the market. The UK’s Medicines and Healthcare products Regulatory Agency began phasing out dextropropoxyphene-containing products, including propoxyphene/acetaminophen combinations, starting in 2005, and completed the ban by the end of 2007. The European Medicines Agency followed in June 2009, recommending withdrawal of marketing authorizations across the entire European Union, citing the risk of fatal overdoses.10PubMed Central. Dextropropoxyphene ban in India: Is there a case for reconsideration? India also eventually banned the drug, though the timeline there generated debate about whether withdrawal was premature given propoxyphene’s low cost and wide availability in a country with fewer affordable pain management alternatives.
The staggered global withdrawal created a natural experiment. In countries where propoxyphene was removed earlier, researchers could observe whether overdose deaths declined and whether substitute medications caused new problems. The overall picture suggested that removing propoxyphene reduced opioid-related fatalities without causing a surge in harm from replacement drugs, though the transition was not seamless everywhere.
What Happened to Patients After the Withdrawal
When propoxyphene disappeared from pharmacy shelves, millions of patients needed a new plan. Studies tracking what happened to these patients reveal a complicated picture. In one analysis, propoxyphene users experienced an abrupt 69% drop in their average daily opioid dose (measured in morphine milligram equivalents) after the withdrawal, compared to just a 14% decline in a comparison group. About a third of former propoxyphene users stopped taking opioids entirely. Tramadol and hydrocodone were the most common substitutes for those who continued opioid therapy.11Medical care. Response to Propoxyphene Market Withdrawal: Analgesic Substitutes, Doses, and Adverse Events
An interesting secondary finding involved acetaminophen exposure. Before the withdrawal, about 12% of propoxyphene users were receiving four grams or more of prescription acetaminophen per day, a dose now considered the upper safe limit for most adults. After the switch, that proportion dropped to around 2%, likely because the combination product had been contributing a substantial acetaminophen load that patients and prescribers had not always been tracking carefully.12Medical care. Response to Propoxyphene Market Withdrawal: Analgesic Substitutes, Doses, and Adverse Events The risk of acetaminophen toxicity from combination products is an underappreciated problem, because patients sometimes take additional over-the-counter acetaminophen without realizing their prescription already contains it.
A separate study of veterans found that the propoxyphene withdrawal pushed a meaningful number of chronic opioid users off opioids altogether. Those affected by the withdrawal were roughly three times more likely to discontinue opioid use than a historical comparison group from before the ban.13PubMed Central. The Influence of Propoxyphene Withdrawal on Opioid Use in Veterans Adverse events in both groups remained rare, suggesting that many of these patients either found non-opioid alternatives or had been taking propoxyphene more out of habit than genuine need. The withdrawal, in effect, served as a forced reassessment of whether opioids were still necessary for these patients.
Propoxyphene on Drug Screens
Even though propoxyphene has been off the market for over a decade, it still shows up in discussions about urine drug testing. Many standard drug screening panels included a propoxyphene-specific test, and some point-of-care devices still have that panel slot. Understanding how these tests work matters for two reasons: forensic cases involving old stockpiles, and false positives from other medications.
Testing for propoxyphene in urine is complicated by the metabolite problem. Norpropoxyphene persists in the body much longer than the parent drug, so most of what a urine test detects is the metabolite rather than propoxyphene itself. Different immunoassay platforms vary widely in how well they detect norpropoxyphene. One evaluation found that a commonly used immunoassay (EMIT II) had only 7% cross-reactivity with norpropoxyphene, while a competing platform (OnLine) showed 77% cross-reactivity. This meant the EMIT assay missed many positive samples because it was essentially blind to the metabolite that dominated urine specimens.14Journal of Analytical Toxicology. Evaluation of the OnLine Immunoassay for Propoxyphene: Comparison to EMIT II and GC-MS A newer point-of-care device showed much better performance, achieving about 99% agreement with confirmatory gas chromatography–mass spectrometry testing.15Journal of Analytical Toxicology. Evaluation of the Triage PPY On-Site Testing Device for the Detection of Dextropropoxyphene in Urine
False positives are the more relevant concern today. An analysis of electronic health records found that ranitidine, a common heartburn medication (itself since removed from the market for unrelated reasons), produced a false positive on the propoxyphene immunoassay channel at higher concentrations.16Journal of Analytical Toxicology. Analysis of Electronic Health Records Reveals Medication-Related Interference on Point-of-Care Urine Drug Screening Assays Diphenhydramine (Benadryl) and tricyclic antidepressants were also identified as causing cross-reactivity on propoxyphene screening tests.17Journal of Analytical Toxicology. Evaluation of the Triage PPY On-Site Testing Device for the Detection of Dextropropoxyphene in Urine Since propoxyphene is no longer prescribed, a positive result on a propoxyphene panel today almost certainly reflects either a false positive from one of these cross-reactive substances, use of an illicitly obtained old supply, or a testing error. Confirmatory testing with mass spectrometry is needed to tell the difference.
The Acetaminophen Side of the Equation
Discussions about propoxyphene/acetaminophen tend to focus on the opioid component, but the acetaminophen in the combination carried its own risks. Acetaminophen is safe at recommended doses for most people, but the margin between a therapeutic dose and a toxic one is narrower than many realize. The maximum recommended daily dose for adults is generally four grams, though many clinicians now suggest a lower ceiling of three grams for people who drink alcohol or have any degree of liver compromise.
The combination product typically contained 650 mg of acetaminophen per tablet. A patient taking the maximum prescribed dose of propoxyphene/acetaminophen throughout the day could easily approach or exceed four grams of acetaminophen from the prescription alone. Adding an over-the-counter cold remedy or headache tablet containing acetaminophen could push the total well into the danger zone. Acetaminophen overdose is the leading cause of acute liver failure in the United States, and a substantial proportion of those cases involve unintentional overdoses from combination products, where patients simply did not realize how much acetaminophen they were taking across multiple medications.
The post-withdrawal data mentioned earlier showed that removing propoxyphene/acetaminophen from the market had the side benefit of reducing the number of patients exposed to high daily acetaminophen doses. This accidental benefit highlights a broader issue with combination opioid/acetaminophen products: they can mask how much acetaminophen a patient consumes, because the focus of both the prescriber and the patient is usually on the opioid component.
Why Some Countries Debated the Ban
Not everyone agreed that withdrawing propoxyphene was the right call. In countries like India, where the drug was inexpensive and widely available, some pharmacologists argued that the blanket ban was imported from wealthier nations where alternative painkillers were readily accessible and affordable.18PubMed Central. Dextropropoxyphene ban in India: Is there a case for reconsideration? The argument was that propoxyphene’s cardiac risks, while real, primarily manifested in overdose or with long-term accumulation, and that in settings where patients had few other affordable options, the calculus of risk versus benefit looked different.
This debate touches on a recurring tension in global drug regulation. Safety data often comes from well-resourced countries with older populations taking many medications simultaneously. The same drug might pose different risks in a younger population with less polypharmacy. Ultimately, most regulatory agencies decided that a weak opioid with meaningful cardiac toxicity and a tendency to accumulate unpredictably was too hard to use safely, regardless of setting. But the conversation raised legitimate questions about whether one-size-fits-all drug withdrawals serve every population equally well.
If You Find Old Propoxyphene at Home
Because propoxyphene/acetaminophen was so widely prescribed before 2010, old bottles still surface in medicine cabinets, particularly in the homes of elderly patients or after a family member passes away. These medications should not be taken under any circumstances. Beyond the cardiac and accumulation risks that led to the ban, the drug degrades over time, and expired opioid formulations can break down into unpredictable byproducts.
The FDA recommends disposing of unused opioids through drug take-back programs, which many pharmacies and law enforcement agencies host periodically. If no take-back option is available, the FDA’s guidance for most opioids is to mix the tablets with an unpalatable substance like coffee grounds or dirt, place the mixture in a sealed container, and throw it in the household trash. Flushing is recommended for some opioids but not universally. The goal is to prevent accidental ingestion by children, pets, or anyone who might encounter the medication. Given that propoxyphene’s narrow therapeutic window and cardiac toxicity make even a single accidental dose potentially dangerous, prompt disposal is worth the small effort.